Introduction
============

Somatic mutations in the epidermal growth factor receptor (*EGFR*) gene are present in a subset of non-small cell lung cancer (NSCLC). *EGFR* mutations occur in the tyrosine kinase domain, mostly involving in-frame deletions in exon 19 and a point mutation (L858R) in exon 21, leading to constitutive activation of EGFR \[[@b1-crt-2013-120],[@b2-crt-2013-120]\]. *EGFR* mutations are associated with increased sensitivity to specific EGFR tyrosine kinase inhibitors (TKIs), and repeatedly confirmed as a predictive and prognostic factor for EGFR TKIs \[[@b3-crt-2013-120]-[@b5-crt-2013-120]\].

Mutation analysis for *EGFR* is essential for the guidance of treatment decisions, regarding the use of EGFR TKIs, and is becoming a standard recommendation in the pretreatment work-up of patients with lung adenocarcinoma \[[@b6-crt-2013-120],[@b7-crt-2013-120]\]. Although *EGFR* mutation status is associated with a high response rate, all patients eventually develop acquired resistance, and progression-free survival (PFS), reaching approximately 10 months \[[@b8-crt-2013-120],[@b9-crt-2013-120]\].

However, predictive or prognostic factors for EGFR TKI, other than *EGFR* mutation, have not been well elucidated. A pragmatic prognostic model, which integrates potential relevant factors, has not been developed in *EGFR* mutant NSCLC. Based on these findings, there is an urgent need for a robust prognostic model for prediction of PFS for EGFR TKI in patients with NSCLC. The aim of this study was to develop a pragmatic nomogram for prediction of PFS for EGFR TKI in *EGFR* mutant NSCLC.

Materials and Methods
=====================

1. Study population
-------------------

We retrospectively analyzed a consecutive database of NSCLC patients treated with either gefitinib or erlotinib at Seoul National University Hospital, between January 2002 and December 2011. Inclusion criteria were as follows: 1) pathology-confirmed, 2) recurred or metastatic NSCLC, 3) underwent *EGFR* mutation test, and 4) receiving gefitinib or erlotinib as a palliative chemotherapy. Gefitinib was administered orally, at a dose of 250 mg daily, and erlotinib was administered at a dose of 150 mg daily, until tumor progression, death, significant uncontrolled toxicity, or patient refusal. Mutational analysis of *EGFR* exons 18, 19, 20, and 21 was performed, as previously described \[[@b10-crt-2013-120],[@b11-crt-2013-120]\]. In brief, coding sequences from exon 18 to 21 were amplified by polymerase chain reaction (PCR) with both forward and reverse sequence-specific primers \[[@b10-crt-2013-120],[@b11-crt-2013-120]\]. PCR fragments were sequenced and analyzed in both sense and antisense directions. All sequence variants were confirmed by sequencing the products of independent PCR amplifications in both directions. Chest computed tomography scans were performed every 8 to 12 weeks as a routine clinical procedure, and additionally as needed to confirm patient response and for assessment of disease progression. The treatment response was evaluated using Response Evaluation Criteria in Solid Tumors criteria \[[@b12-crt-2013-120]\]. PFS was measured from the first day of TKI treatment until the first objective sign of disease progression or death. This study was reviewed and approved by the Institutional Review Board of Seoul National University Hospital.

2. Constructing a model
-----------------------

Details of model construction are described in our previous report \[[@b13-crt-2013-120]\]. We constructed the nomogram, using the Cox proportional hazard regression (PHR) model for the survival data \[[@b14-crt-2013-120]\]. Beta-coefficients from the model were used for allocation of points. Univariate Cox PHR analyses were performed to evaluate the prognostic values of each variable, followed by multivariate Cox PHR analysis. Multicollinearity between variables was also tested, and one of the variables, which showed multicollinearity, was removed in the model. The final multivariate model was chosen on the basis of the stepwise procedure, as well as consideration of the clinical or biologic importance of the variables in the model. Based on the prediction model with identified predictive and prognostic factors, a nomogram was built for prediction of PFS.

3. Evaluating model performance
-------------------------------

The model performance was evaluated, in terms of the discrimination and calibration performance. Discrimination is the ability of the predictor to separate patients with different responses or events. Discrimination for survival data was evaluated, using the C statistic with concordance index (C-index) \[[@b15-crt-2013-120]\], which is similar in concept to the area under the receiver operating characteristic (ROC) curve in the logistic model \[[@b16-crt-2013-120]\], but appropriate for the censored data \[[@b17-crt-2013-120],[@b18-crt-2013-120]\]. The concordance index provides the probability that given two randomly selected patients, the patient with the worse outcome will in fact have a worse outcome prediction. The C-index ranges from 0 to 1, with 1 indicating perfect concordance, 0.5 indicating no better concordance than chance, and 0 indicating perfect discordance. In general, the model is considered relatively good for discrimination with values above 0.70. ROC curve for the survival data was drawn, using the methods proposed by Heagerty et al. \[[@b19-crt-2013-120]\].

Calibration is the agreement between the observed probability and predicted probability produced by the model \[[@b15-crt-2013-120]\]. The nomogram was calibrated by plotting the nomogram's predicted 12-month PFS rate against the actually observed PFS rate, as calculated using the Kaplan-Meier method. Patients were divided into eight groups, using the quartiles of the predicted risk as the cutoff points. We used the bootstrapping re-sampling method (400 repetitions) in order to obtain relatively unbiased estimates and to check the interval validation.

Statistical analyses were performed, using STATA statistical software ver. 11.0 (STATA, College Station, TX) and R software ver. 2.13.2 (<http://www.r-project.org>). R package with the Design, and survcomp libraries (available at URL: <http://cran.r-project.org/web/packages/>) were used.

Results
=======

Clinical characteristics of the 306 patients are shown in [Table 1](#t1-crt-2013-120){ref-type="table"}. The median PFS was 11.2 months (95% confidence interval \[CI\], 9.9 to 12.5 months), and 181 progression events had occurred. The 6-, 12-, and 18-month PFS rates, for the entire patient cohort, were 73.5%, 46.0%, and 25.1%, respectively. Response rate to EGFR TKI was 71.9% (95% CI, 66.9% to 76.9%).

1. Nomogram predicting PFS
--------------------------

We performed a univariate and multivariate Cox PHR analysis; [Table 2](#t2-crt-2013-120){ref-type="table"} shows the results. In the univariate Cox PHR model, disease status, performance status, chemotherapy line, *EGFR* mutation status, response to TKI, liver metastasis, and bone metastasis showed association with PFS. Before constructing a multivariate Cox PHR model, colinearity was assessed, and the association between the variables was calculated, using the chi-square test for categorical variables. Significant association was observed between *EGFR* mutation status and response to TKI (chi-square p \< 0.001). Liver metastasis and bone metastasis showed significant multicollinearity (chi-square p \< 0.031). Therefore, liver metastasis and *EGFR* mutation status were not included in the multivariate Cox PHR model. Based on the results of multivariate analysis, the final nomogram model demonstrated the best fit and included all 5 variables ([Fig. 1](#f1-crt-2013-120){ref-type="fig"}). The nomogram was developed for prediction of PFS, and can assign numeric predictions points for the risk of progression at 6, 12, and 18 months. Its C-index was 0.708 (95% CI, 0.659 to 0.758), and it appeared to be accurate. [Fig. 2](#f2-crt-2013-120){ref-type="fig"} shows the ROC curve and [Fig. 3](#f3-crt-2013-120){ref-type="fig"} shows the calibration plot.

Discussion
==========

In the current study, we developed the nomogram for prediction of PFS for EGFR TKI in NSCLC patients with *EGFR* mutation, based on the clinical and molecular characteristics. These practical models were internally validated and showed a good model performance in terms of calibration and discrimination. This nomogram may be useful in predicting when primary or acquired resistance to EGFR TKI will develop.

To date, several prognostic models \[[@b20-crt-2013-120],[@b21-crt-2013-120]\] have been reported in NSCLC patients receiving EGFR TKI. Florescu et al. \[[@b20-crt-2013-120]\], who analyzed patients treated with erlotinib in the National Cancer Institute of Canada Clinical Trial Group Study BR21, identified the ten following clinical factors associated with overall survival: Eastern Cooperative Oncology Group performance status, smoking, weight loss, anemia, lactate dehydrogenase, time from diagnosis, response to prior treatment, ethnicity, and number of prior regimens. Florescu et al. \[[@b20-crt-2013-120]\] developed a clinical prognostic index, which allocates the scores to ten clinical factors, and categorized patients according to four subgroups. Among these 10 factors, Eastern Cooperative Oncology Group (ECOG) performance status and smoking were also valid in our model.

In addition to the clinical factors, several molecular markers are also known to be associated with PFS or resistance for EGFR TKI. Expression of thyroid transcription factor-1 \[[@b22-crt-2013-120]\] and estrogen receptor beta \[[@b23-crt-2013-120]\] showed an association with longer PFS for EGFR TKI, while K-ras mutation \[[@b24-crt-2013-120],[@b25-crt-2013-120]\] and phosphoinositide-3-kinase catalytic alpha mutation \[[@b24-crt-2013-120]\] were associated with shorter PFS. Incorporation of these molecular markers into the nomogram can result in construction of a better prediction model.

The current study has some limitations. First, our nomogram was not externally validated using an independent data set. We performed only the internal validation, using the bootstrap method. It will be necessary to validate our nomogram by application in independent patients in other patient populations particularly Western patients. Second, response evaluation was repeatedly performed every 8-12 weeks, based on routine practice pattern. PFS might not be accurate due to inconsistent evaluation interval. Despite these limitations, the current study first developed the practical nomogram, regarding EGFR TKIs efficacy.

Conclusion
==========

We developed a simple and precise nomogram that can be used for prediction of the PFS to EGFR TKIs in NSCLC patients with *EGFR* mutant. This prognostic nomogram can enable physicians to provide patients with an approximation of their prognosis before the initiation of EGFR TKIs treatment. In the clinic, this nomogram may be useful in prediction of when resistance to EGFR TKIs will occur, and provide guidance for identification of patients who will have long or short duration benefit from EGFR TKIs.
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###### 

Characteristics of the 306 patients who received gefitinib or erlotinib

                                                                  No. (%) (n=306)
  --------------------------------------------------------------- -----------------
  Age (yr)                                                        
   Median (range)                                                 61 (31-85)
  Gender                                                          
   Male                                                           108 (35.3)
   Female                                                         198 (64.7)
  Disease status                                                  
   Recurred                                                       67 (21.9)
   Initial stage wet IIIB, IV                                     239 (78.1)
  Smoking                                                         
   Never-smoker                                                   222 (72.5)
   Current or ex-smoker                                           76 (24.8)
   Unknown                                                        8 (2.6)
  Pathology                                                       
   Adenocarcinoma                                                 275 (89.9)
   Non-small cell carcinoma NOS                                   23 (7.5)
   Squamous cell carcinoma                                        4 (1.3)
   Others                                                         4 (1.3)
  ECOG PS                                                         
   0                                                              16 (5.2)
   1                                                              209 (68.3)
   2                                                              27 (8.8)
   3                                                              10 (3.3)
   4                                                              2 (0.7)
   Unknown                                                        42 (13.7)
  Liver metastasis                                                
   No                                                             260 (85.0)
   Yes                                                            46 (15.0)
  Bone metastasis                                                 
   No                                                             177 (57.8)
   Yes                                                            129 (42.2)
  Brain metastasis                                                
   No                                                             196 (64.1)
   Yes                                                            110 (35.9)
  EGFR TKI                                                        
   Gefitinib                                                      274 (89.5)
   Erlotinib                                                      32 (10.5)
  Line                                                            
   1st                                                            108 (35.3)
   2nd                                                            178 (58.2)
   3rd or more                                                    20 (6.5)
  *EGFR*mutation                                                  
   Del-19 or L858R                                                290 (67.6)
   Rare mutation[^a)^](#tfn1-crt-2013-120){ref-type="table-fn"}   16 (3.7)
  Treatment response                                              
   Complete response                                              12 (3.9)
   Partial response                                               208 (68.0)
   Stable disease                                                 46 (15.0)
   Progressive disease                                            24 (7.8)
   Not evaluable                                                  16 (5.2)

NOS, not otherwise specified; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.

Rare mutations were defined as any mutation other than del-19 or L858R in exon 21 of the *EGFR* gene.

###### 

Univariate and multivariate Cox proportional hazard regression analysis between clinicopathologic variables and progression-free survival

  Variable                 Univariate   Multivariate                                    
  ------------------------ ------------ -------------- ---------- ------- ------------- ----------
  Disease status                                                                        
   Recurred                1                                      1                     
   Initial metastatic      1.906        1.325-2.742    0.001      2.126   1.434-3.152   \< 0.001
  Pathology                                                                             
   ADC                     1                                      \-                    
   Non-ADC                 0.886        0.548-1.434    0.623      \-      \-            \-
  Smoking                                                                               
   Never                   1                                      \-                    
   Current or ex-smoking   1.237        0.880-1.739    0.220      \-      \-            \-
  ECOG PS                                                                               
   0-1                     1                                      1                     
   2-4                     1.740        1.088-2.783    0.021      1.978   1.210-3.235   0.007
  EGFR TKI                                                                              
   Gefitinib               1                                      \-                    
   Erlotinib               0.910        0.590-1.402    0.668      \-      \-            \-
  Line                                                                                  
   1st                     1                                      1                     
   2nd                     1.270        0.908-1.777    0.163      1.233   0.860-1.767   0.254
   3rd or more             1.925        1.116-3.321    0.019      2.198   1.228-3.936   0.008
  *EGFR* mutation                                                                       
   Del-19 or L858R         1                                      \-                    
   Rare                    4.158        2.358-7.331    \< 0.001   \-      \-            \-
  Response to TKI                                                                       
   Responding              1                                      1                     
   Non-responding          3.056        2.223-4.200    \< 0.001   3.141   2.228-4.426   \< 0.001
  Liver metastasis                                                                      
   No                      1                                      \-                    
   Yes                     1.546        1.067-2.240    0.021      \-      \-            \-
  Bone metastasis                                                                       
   No                      1                                      1                     
   Yes                     1.730        1.286-2.327    \< 0.001   1.384   1.001-1.913   0.049
  Brain metastasis                                                                      
   No                      1                                      \-                    
   Yes                     1.241        0.919-1.677    0.160      \-      \-            \-

HR, hazard ratio; CI, confidence interval; ADC, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; *EGFR*, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
